Wegovy 1.0 mg Prefilled Pen

Wegovy 1.0 mg FlexTouch is a pre-filled pen containing 1 mg of semaglutide. It is a prescription-only medicine used as part of a comprehensive weight-management programme alongside a reduced-calorie diet and increased physical activity in eligible patients. View the official UK Wegovy prescribing information

What is Wegovy 1.0 mg?

Wegovy 1.0 mg contains semaglutide, a GLP-1 receptor agonist. The medicine is administered by subcutaneous injection once weekly according to the treatment schedule prescribed by a healthcare professional.

The 1.0 mg strength is used during dose escalation. According to the current UK prescribing information, the usual escalation schedule progresses through 0.25 mg during weeks 1–4, 0.5 mg during weeks 5–8, 1 mg during weeks 9–12, and 1.7 mg during weeks 13–16 before the maintenance dose. Dose escalation may be adjusted if clinically appropriate, particularly where gastrointestinal symptoms occur.

Patients should not change their Wegovy dose without advice from their prescriber.

How does Wegovy work?

Semaglutide acts on GLP-1 receptors and can influence appetite and feelings of fullness. It is used alongside dietary changes and increased physical activity as part of a structured weight-management approach.

Treatment suitability varies between individuals. A healthcare professional should assess whether Wegovy is appropriate based on factors such as medical history, current medicines and eligibility criteria.

Wegovy 1.0 mg dose information

Wegovy 1.0 mg is not normally the initial dose. It is a dose-escalation strength used after the earlier strengths have been tolerated.

The current UK Summary of Product Characteristics specifies:

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Maintenance: 2.4 mg once weekly

For certain adults with obesity, the prescribing information also provides for a possible increase to 7.2 mg once weekly after at least four weeks at 2.4 mg, where clinically appropriate.

Your prescriber will determine the appropriate treatment schedule for you.

Important safety information

Wegovy is a prescription-only medicine in the UK. It should only be supplied and used in accordance with the applicable prescription requirements and under appropriate healthcare supervision.

Read the official patient information leaflet before using Wegovy. Tell your healthcare professional about other medicines you take and any relevant medical conditions.

If significant gastrointestinal symptoms occur during dose escalation, the UK prescribing information advises that delaying escalation or returning to the previous dose may be considered until symptoms improve.

Wegovy should not be used together with another semaglutide-containing medicine or another GLP-1 receptor agonist unless specifically directed by an appropriate healthcare professional.

Product information
Information Details
Active ingredient Semaglutide
Strength 1 mg per dose
Dosage form Solution for injection
Administration Subcutaneous injection
Frequency Once weekly according to the prescribed schedule
Device FlexTouch pre-filled pen
Pack One multi-dose pre-filled pen with four doses
Legal category Prescription-only medicine
Marketing authorisation holder Novo Nordisk A/S

The current UK SmPC states that one Wegovy 1 mg FlexTouch pen contains four 1 mg doses and that the pen is designed for use with compatible disposable needles up to 8 mm in length.

Related Wegovy information

If you are comparing different strengths, visit our [Wegovy 0.5 mg Prefilled Pen] page and [Wegovy 1.7 mg Prefilled Pen] page for additional product information.

You can also explore our [Wegovy Products] category for related products and our [Weight Management Guide] for educational information about prescription weight-management treatments.

For official UK information, consult the Wegovy 1 mg Summary of Product Characteristics and the official patient information supplied with the medicine.

Frequently Asked Questions
What is Wegovy 1.0 mg?

Wegovy 1.0 mg is a semaglutide-containing prescription medicine supplied as a FlexTouch pre-filled pen. It is one of the dose-escalation strengths used during Wegovy treatment.

Is Wegovy 1.0 mg the starting dose?

No. The UK prescribing schedule normally begins with 0.25 mg and increases gradually. The 1 mg dose is used during weeks 9–12 of the standard escalation schedule.

How often is Wegovy 1.0 mg used?

Wegovy is administered once weekly according to the treatment schedule prescribed by a healthcare professional.

What is the active ingredient in Wegovy 1.0 mg?

The active ingredient is semaglutide, a GLP-1 receptor agonist.

Can I increase to 1.0 mg without speaking to my doctor?

No. Dose escalation should follow the prescribing instructions and the advice of your healthcare professional.

Where can I find official Wegovy information?

The UK electronic Medicines Compendium provides the current Summary of Product Characteristics and patient information for Wegovy. Wegovy 1 mg SmPC on eMC